SARS-CoV2 Infection Clinical Trial
Official title:
Coronavirus Pediatric Serological Study
The Coronavirus Pediatric Serological Study's aim is to provide a better insight of children's immune response after SARS-CoV-2 infection. Serological tests were conducted on blood samples taken 3 to 5 months after the children's viral infection. The study was performed in collaboration with the Institute of Medical Immunology, were antibody levels were measured and immunoglobulin subclasses profiles were studied.
The hospital laboratory provided us the list of children under 15 years old tested for SARS-CoV-2 in Saint-Pierre Hospital (Brussels) by PCR on nasopharyngeal swab between March 1 2020 and December 31 2020. The medical files of all children that were tested positive for SARS-CoV-2 were reviewed and clinical information was collected. For each positive child, the family was contacted by phone 3 months after the proven viral infection in order to ask permission to take a single blood test. Covid19 serologies were performed in the hospital laboratory, and blood samples were then sent to the Institute of Medical Immunology, were antibody levels and immunoglobulin subclasses were studied. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Recruiting |
NCT05311410 -
Viral Kinetics of SARS-CoV-2 in Patients With COVID-19 in the Intensive Care Unit Undergoing Dental Procedures
|
N/A | |
| Active, not recruiting |
NCT05073718 -
SARS-CoV-2 and Acetylsalicylic Acid (SARA)
|
Phase 3 | |
| Completed |
NCT05055492 -
The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions
|
N/A | |
| Completed |
NCT05060510 -
The School SPIT Study - COVID-19 Testing in Secondary Schools
|
N/A | |
| Completed |
NCT05055505 -
The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions
|
N/A | |
| Completed |
NCT05054218 -
COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
|
||
| Completed |
NCT05449392 -
Topical Antibacterial Agents for Prevention of COVID-19
|
Phase 1 | |
| Completed |
NCT05076253 -
Efficacy of Ivermectin in COVID-19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05172024 -
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
|
||
| Terminated |
NCT05593770 -
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
|
Phase 2/Phase 3 | |
| Completed |
NCT05030974 -
RECOVAC Repeated Vaccination Study
|
Phase 4 | |
| Withdrawn |
NCT05067946 -
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05013034 -
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
|
Phase 2 | |
| Withdrawn |
NCT05393999 -
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
|
Phase 2 | |
| Recruiting |
NCT05047783 -
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
|
Phase 2 | |
| Not yet recruiting |
NCT05116657 -
Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
|
||
| Recruiting |
NCT04590222 -
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
|
||
| Completed |
NCT04551911 -
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
|
Phase 2 | |
| Completed |
NCT04953039 -
Use of Saliva for COVID-19 Diagnosis
|